RESUMO
OBJECTIVE: Some genetic alterations are involved in ovarian carcinogenesis. Since some benign and borderline tumors may represent early steps in ovarian carcinogenesis, analysis of precursor lesions could provide evidence that an accumulation of genetic events is required in order for normal ovarian epithelium to generate benign, borderline, malignant tumors. Few pre-invasive ovarian tumors have been studied so far. METHODS: 60 cases of ovarian epithelial tumors, including benign, borderline, and malignant tumors, were analyzed for microsatellite instability (MSI) by gel analysis of paired germ line and tumor DNA. PCR amplification was performed using the panel of 5 microsatellite markers recommended by the NCI (BAT25, BAT26, D2S123, D5S346, D17S250) and 6 additional markers (D1S160, D1S162, D7S522, D11S860, D17S855, D17S932). RESULTS: In this study, D2S123 and D5S346 were the most frequently altered markers in malignant ovarian tumors and D11S860 locus showed MSI in 4 adenomas, 4 boderline tomors, and 10 malignant tumors. Other markers displayed instability with only one or two tumors showing MSI. On the basis of NCI criteria, most benign tumors demonstrat microsatellite stable (MSS). In the borderline tumors, 10 tumors revealed MSS, 8 tumors had low-frequency MSI (MSI-L), and two tumors had high frequency MSI (MSI-H). In the malignant tumors, 6 tumors revealed MSS, 2 tumors had MSI-L, and 12 tumors had high MSI-H. CONCLUSION: According to the results, MSL-H is more frequently seen in the malignant tumors. D2S123 and D5S346 were the most frequently altered markers in the malignant tumors, and D11S860 locus may be involved in early step of carcinogenesis.
Assuntos
Adenoma , Carcinogênese , DNA , Epitélio , Células Germinativas , Instabilidade de Microssatélites , Repetições de Microssatélites , Reação em Cadeia da PolimeraseRESUMO
Mature cystic teratoma represents 10~20% of all ovarian neoplasms in women during the second and third decades of life. Malignant transformation rarely takes place in this tumor, and is observed in approximately 1~2% of all cases. The most common malignancy developing in mature cystic teratoma is squamous cell carcinoma. The prognosis for patients with malignant transformation of mature cystic teratoma is poor and because of the rarity of malignant degeneration, the surgical and postoperative management is not established. A case of a stage IIIb squamous cell carcinoma which developed in a mature cystic teratoma in a 47-year-old female who was disease free after tumor debulking surgery and subsequent treatment of five cycles of bleomycin (30 mg iv injection Day 1), ifosfamide (1 g/m(2) iv injection Days 1-5), and cisplatin (50 mg/m(2) iv injection Day 1) is presented and issues regarding the diagnosis and management of this rare complication are discussed.
Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Bleomicina , Carcinoma de Células Escamosas , Cisplatino , Diagnóstico , Ifosfamida , Neoplasias Ovarianas , Prognóstico , TeratomaRESUMO
Mature cystic teratoma represents 10~20% of all ovarian neoplasms in women during the second and third decades of life. Malignant transformation rarely takes place in this tumor, and is observed in approximately 1~2% of all cases. The most common malignancy developing in mature cystic teratoma is squamous cell carcinoma. The prognosis for patients with malignant transformation of mature cystic teratoma is poor and because of the rarity of malignant degeneration, the surgical and postoperative management is not established. A case of a stage IIIb squamous cell carcinoma which developed in a mature cystic teratoma in a 47-year-old female who was disease free after tumor debulking surgery and subsequent treatment of five cycles of bleomycin (30 mg iv injection Day 1), ifosfamide (1 g/m(2) iv injection Days 1-5), and cisplatin (50 mg/m(2) iv injection Day 1) is presented and issues regarding the diagnosis and management of this rare complication are discussed.
Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Bleomicina , Carcinoma de Células Escamosas , Cisplatino , Diagnóstico , Ifosfamida , Neoplasias Ovarianas , Prognóstico , TeratomaRESUMO
This study was performed to assess the significance of plasma level and histochemical character of carcinoembryonic antigen(CEA) in early diagnosis and prognosis of ovarian tumor. Plasma level of CEA was measured using EIA method and immunohistochemical tissue staining of CEA was done using biotin-strepto avidin complex immunoperoxidase technique. The percentage of patients with positive CEA level(above 2.5 ng/ml) was 23.1%(6/26) in malignant ovarian tumor and 15.6%(12/77) in benign ovarian tumor. Positive tissue staining of CEA was 42.3%(11/26) in malignant ovarian tumor and 19.5%(15/77) in benign ovarian tumor. In histologic typing, positive tissue staining of CEA was 18.1%(2/11) in serous cystadenocarcinoma, 85.7%(6/7) in mucinous cystadenocarcinoma, 37.5%(3/8) in other malignant ovarian tumors, 7.1%(1/15) in serous cystadenoma, 7.1%(1/14) in mucinous cystadenoma and 27.1%(13/48) in other benign ovarian tumors. Among 5 cases of malignant ovarian tumors with positive CEA level, 3 cases(60%) showed positive tissue staining of CEA, whereas among 21 cases of malignant ovarian tumors with negative CEA level, 8 cases (38.1%) showed positive tissue staining of CEA. However, among 11 cases of benign ovarian tumors with positive CEA level, 4 cases(36.4%) showed positive tissue staining of CEA, whereas among 66 cases of benign ovarian tumors with negative CEA level, 11 cases(16.7%) showed positive tissue staining of CEA. In the 3 year follow-up study of 12 cases with malignant ovarian tumor, among 3 cases with positive tissue staining of CEA, 2 cases(66.7%) survived. In 9 cases with negative tissue staining of CEA, 6 cases(66.7%) survived. In conclusion, these results suggest that the measurement of tumor CEA may be of value in the differential diagnosis of malignant and benign ovarian tumor, especially in diagnosing mucinous cystadenocarcinoma. However, due to the small amount of cases available for study, it was difficult to determine the correlation between the prognosis and tissue CEA staining of ovarian tumors.
Assuntos
Humanos , Avidina , Antígeno Carcinoembrionário , Cistadenocarcinoma Mucinoso , Cistadenocarcinoma Seroso , Cistadenoma Mucinoso , Cistadenoma Seroso , Diagnóstico Diferencial , Diagnóstico Precoce , Seguimentos , Técnicas Imunoenzimáticas , Plasma , PrognósticoRESUMO
Human epithelial cell line immortalized with Ad12-SV40 hybrid virus was transfected with plasmid containing HPV-16 gene. Among these clones, clone-3 and clone-6 showed neoplastic transformation properties of contact inhibition, anchorage independence and cellular adhesion after 7 subcultures. The results suggest that SV40 gene in the immortalized human cell system be in concert with HPV-16 in the process of neoplastic transformation of human cells. While TGF-Beta1(5ng/ml) inhibited growth of contml cells and clone-1 cells which did not show transformation, there was no significant change on the growth of clone-3 cells with transformation properties. When transcriptional level of fibronectin on control cells and clone-3 cells were analyzed with northern blot technique, transcription of fibronectin an clone-3 cells were higher, as compared with control cells. RNA hybridization techniques were performed to compare trasnscriptional levels of TGF-Beta1 between control cells and clone-3 cells. RNA level on clone-3 cells with transformation properties was higher than on control cells. These studies indicate that TGF-Beta1 is associated with increases of fibronectin, which may lend to changes of TGF-Beta receptor and loss of its inhibitory action on the transformed cells. Thus, it seems that loss of inhibitory action of TGF-Beta which is mediated by changes of fibronectin may account for a possible mechanism of action in the HPV-16 induced transformation of human cells.